Table 4.
Univariate analysis for risk factors for Day 14 and Day 30 mortalities, and unfavorable outcomes at end of teicoplanin therapy
|
Variables |
Day 14 mortality |
Day 30 mortality |
Unfavorable outcome |
|||
|---|---|---|---|---|---|---|
| OR | p value | OR | p value | OR | p value | |
| Age |
1.01 |
0.3749 |
1.02 |
0.0138 |
1.02 |
0.0628 |
| Sex (male to female) |
0.67 |
0.3025 |
0.84 |
0.5748 |
1.06 |
0.8281 |
| Charlson comorbidity index |
1.10 |
0.7972 |
2.73 |
0.0974 |
1.04 |
0.4988 |
| Onset in ICU |
1.08 |
0.8307 |
2.71 |
0.1147 |
1.44 |
0.1587 |
| Presence of metastatic foci |
1.79 |
0.1337 |
1.48 |
0.2079 |
1.21 |
0.5225 |
| Endocarditis |
0.95 |
0.9338 |
2.17 |
0.8592 |
2.16 |
0.0430 |
| Septic shock |
3.08 |
0.0083 |
18.11 |
<0.0001 |
8.44 |
<0.0001 |
| Primary bacteremia |
0.90 |
0.7724 |
0.69 |
0.1781 |
0.73 |
0.2215 |
| Cardiovascular diseases |
1.04 |
0.9336 |
1.63 |
0.1452 |
1.54 |
0.1503 |
| Respiratory diseases |
0.71 |
0.4507 |
1.01 |
0.9698 |
0.92 |
0.7860 |
| Neurologic diseases |
0.60 |
0.2247 |
0.79 |
0.4384 |
0.77 |
0.3388 |
| Gastrointestinal tract diseases |
0.42 |
0.0415 |
0.48 |
0.0157 |
0.90 |
0.6976 |
| Hepatobiliary diseases |
0.62 |
0.3419 |
0.56 |
0.1292 |
0.65 |
0.1934 |
| Genitourinary tract diseases |
0.98 |
0.9619 |
1.52 |
0.1338 |
1.31 |
0.2996 |
| Endocrinologic diseases |
1.07 |
0.8595 |
1.43 |
0.2029 |
1.47 |
0.1290 |
| Malignancies |
0.78 |
0.5217 |
0.94 |
0.8247 |
1.01 |
0.9860 |
| Autoimmune diseases |
4.27 |
0.0044 |
1.98 |
0.1543 |
0.72 |
0.5218 |
| Immunosuppression |
1.45 |
0.3246 |
1.39 |
0.2654 |
1.19 |
0.5264 |
| Abnormal white blood cell count |
|
|
|
|
|
|
| < 4,000/μL |
1.26 |
0.6380 |
0.71 |
0.4259 |
0.79 |
0.5671 |
| > 12,000/μL |
0.49 |
0.0851 |
0.59 |
0.0798 |
0.89 |
0.6658 |
| Anemia |
1.22 |
0.5959 |
1.11 |
0.7155 |
1.38 |
0.2135 |
| Thrombocytopenia |
4.20 |
0.0003 |
2.43 |
0.0017 |
1.35 |
0.2357 |
| Hypoalbuminemia |
3.40 |
0.2427 |
1.12 |
0.8368 |
2.09 |
0.1375 |
| Abnormal liver function with clinical significance |
6.94 |
0.0214 |
3.04 |
0.1815 |
1.85 |
0.4593 |
| Abnormal renal function |
1.34 |
0.4481 |
2.06 |
0.0168 |
1.58 |
0.0856 |
| C-reactive protein |
1.00 |
0.9269 |
1.00 |
0.9232 |
1.04 |
0.0166 |
| Without effective treatment within 48 hours |
0.77 |
0.5428 |
1.20 |
0.5698 |
0.87 |
0.6310 |
| Adequate loading dose |
0.932 |
0.8488 |
0.76 |
0.3335 |
0.93 |
0.7845 |
| Combination therapy |
1.46 |
0.3666 |
0.76 |
0.4481 |
0.60 |
0.1322 |
| Teicoplanin MIC by broth dilution |
0.76 |
0.5983 |
1.65 |
0.1712 |
1.02 |
0.9451 |
| Teicoplanin MIC by Etest |
0.90 |
0.7976 |
1.00 |
0.9949 |
1.15 |
0.6451 |
| Sequence types (ST5, ST239 compared to other types) | ||||||
| ST5 |
0.664 |
0.4758 |
0.61 |
0.2047 |
0.76 |
0.4346 |
| ST239 | 1.54 | 0.2992 | 0.85 | 0.6109 | 1.02 | 0.9531 |